BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

EirGenix and Sandoz Sign USD 152 Million Global Deal for Pertuzumab Biosimilar

EirGenix Inc. announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQ...

November 13, 2025 | News

Hasten Biopharmaceutical Completes 70 Marketing Authorization Transfers and Builds End-to-End Commercial Network Across Asia-Pacific

Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced that while completing 70 Marketing Authorization Transfers (MAT) for its Asia-Pacific pro...

November 05, 2025 | News

Nielsen BioSciences and Maruho Expand Licensing Agreement for CANDIN Across Key Asian Markets

Expansion of licensing agreement extends CANDIN’s development to key Asian growth markets including China, South Korea and Taiwan--and broadens the...

October 27, 2025 | News

Asia University and NucleicAI Forge Alliance to Build Taiwan’s First Sovereign AI Life Science Data Platform

Asia University will partner with NucleicAI LLC, a next-generation platform and data company specializing in AI-driven genomics, precision m...

October 15, 2025 | News

Glac Biotech secures US FDA GRAS for CP-9, cementing Taiwan’s multi-GRAS lead

Glac Biotech, a Taiwan-based developer of probiotics and postbiotics, today announced that its core probiotic strain CP-9 (Bifidobacterium lactis CCTCC M 2...

September 16, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Taiwan’s Senhwa Biosciences Gains FDA IND Clearance for CX-5461 in MYC-Driven B-Cell Lymphomas

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has gran...

September 08, 2025 | News

RemeGen and Santen Form Strategic Alliance on RC28-E for Asia and Greater China

RemeGen Co., a leading Chinese biopharmaceutical company, announced that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Sa...

August 20, 2025 | News

Everest Medicines Secures Full Taiwan Approval for NEFECON® in IgA Nephropathy

Everest Medicines (HKEX 1952.HK) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R...

August 12, 2025 | News

Senhwa Advances CX-5461 into NCI-Sponsored Trial for MYC-Aberrant Lymphoma

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious d...

August 08, 2025 | News

Energenesis Completes Phase I Trial of ENERGI-F705PD, a Novel Oral Therapy for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pha...

August 04, 2025 | News

Senhwa Biosciences’ CX-5461 Selected by U.S. National Cancer Institute for Major Oncology Research Programme

Senhwa Biosciences, Inc., a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, ...

July 17, 2025 | News

DIVA Marks 30 Years with Industry-First Surgical Displays and OLED Breakthroughs in Medical Imaging

DIVA, a professional medical display manufacturer with 30 years of experience, announces three major product developments that reinforce its commitment to ...

July 17, 2025 | News

Fujitsu and Acer Medical to Launch AI-Powered Gait Analysis for Early Dementia and Parkinson’s Detection in Taiwan

Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to dev...

July 16, 2025 | News

Stay Connected